{"database": "lobbying", "table": "lobbying_activities", "rows": [[2340122, "05c66eef-d4b4-49c2-916a-d15e598210d6", "Q3", "DAVIS & HARMAN LLP", 11674, "EMERGENT BIOSOLUTIONS, INC.", 2019, "third_quarter", "HOM", "FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. Reauthorization of the Pandemic and All-Hazards Preparedness Act (H.R. 269/S. 1379). NDAA - provisions related to biological and chemical defense. Department of Defense appropriations for Medical countermeasures. FDA regulatory issues. Issues related to Priority Review Voucher programs. Opioid and heroin legislation. Naloxone access, coprescribing/opioid prescribing guidelines.", "HOUSE OF REPRESENTATIVES,SENATE", 10000, null, 0, 0, "2019-10-10T16:05:38.740000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2340122"], "units": {}, "query_ms": 2.259214990772307, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}